ABUS vs PPL · P/E 5.4, rev $6.2M vs P/E 22, rev $8.46B
Arbutus Biopharma Corp (ABUS) versus PPL Corporation (PPL) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
PPL Corporation (PPL) is a utilities - regulated electric company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported PPL revenue for 2024-12-31 was $8.46B. Net income was $888.0M. Revenue was up 1.8% from 2023-12-31 to 2024-12-31. PPL currently screens at market cap $26.58B and trailing P/E 21.7.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. PPL currently screens at market cap $26.58B and trailing P/E 21.7.
Not investment advice. Open the ABUS and PPL stock pages for the full models.
Not investment advice.